Barry James Maurer
University of Southern California
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Barry James Maurer.
Methods in molecular medicine | 2005
C. Patrick Reynolds; Barry James Maurer
The mainstay of clinical antineoplastic chemotherapy is multiagent combinations, most of which were developed empirically. Because of the desire to speed research and decrease costs, there is increasing interest in moving new drugs into clinical trials in potentially active combinations based on preclinical testing data. Different mathematical models have been proposed for evaluating drug interactions, which can be classified as synergistic (combinations demonstrating greater than the additive activity expected from each agent alone), additive, or antagonistic (drugs showing less activity in combination than expected from the sum of each agent alone). Here, we briefly review some of the principles for testing cytotoxic drug interactions. We focus this review on application of the Combination Index method (as developed by Chou and colleagues) in the evaluation of drug interactions in cell culture assays.
Investigative Ophthalmology & Visual Science | 2008
Parameswaran G. Sreekumar; Jiehao Zhou; Joonhong Sohn; Christine Spee; Stephen J. Ryan; Barry James Maurer; Ram Kannan; David R. Hinton
PURPOSE To evaluate the effect of N-4-hydroxyphenyl retinamide (4-HPR) on experimental laser-induced choroidal neovascularization (CNV) and on the expression and secretion of relevant growth factors by cultured human retinal pigment epithelial (RPE) cells. METHODS CNV was induced by laser photocoagulation in C57BL/6 mice. 4-HPR (0.2 or 1 mg) or vehicle, was injected intraperitoneally twice daily for 14 days. Plasma and tissue levels of 4-HPR were measured by HPLC. CNV was evaluated by fluorescein angiography, histology, and quantitative confocal analysis of isolectin B4 histochemistry on days 7 and 14. Induction of apoptosis and expression and secretion of growth factors was studied in 4-HPR-treated RPE cultures. RESULTS Mice treated with 4-HPR exhibited time- and dose-dependent increases in plasma and tissue 4-HPR levels. CNV lesions showed increased volume with increased vascular leakage and contained fewer lesion-associated RPE in treated versus untreated mice. Treatment of nonpolarized RPE cultures with 4-HPR in the presence of serum resulted in RPE apoptosis; however, apoptosis was minimal in similarly treated highly polarized RPE. Treatment of RPE cells with 4-HPR resulted in the upregulation of VEGF-A and -C (P < 0.05) and Ang-1 (P < 0.01) mRNA and increased secretion of VEGF-A and -C (P < 0.05), whereas pigment epithelium-derived growth factor (PEDF) and thrombospondin (TSP)-1 mRNA expression and secretion were downregulated (P < 0.05). CONCLUSIONS 4-HPR increases lesion size and leakage in laser-induced CNV and is associated with the upregulation of key proangiogenic factors and the downregulation of antiangiogenic factors. Consistent with the preferential loss of RPE in CNV lesions in vivo, 4-HPR induces apoptosis of nonpolarized RPE in the presence of serum.
Archive | 2004
Barry James Maurer; Charles Patrick Reynolds; David W. Yesair; Robert Travis McKee; Stephen W. Burgess; Walter A. Shaw
Molecular Pharmacology | 1999
Barry James Maurer; Michael A. Ihnat; Cindy Morgan; Janice Pullman; Craig O'Brien; Steven W. Johnson; Janet S. Rasey; Marilyn M. Cornwell
Archive | 2004
Barry James Maurer; Charles Patrick Reynolds
Archive | 2005
Barry James Maurer; Charles Patrick Reynolds; David W. Yesair; Robert Travis McKee; Stephen W. Burgess; Walter A. Shaw
Cancer Research | 2004
Barry James Maurer; T. Frgala; Bee-Chun Sun; J. Vlckova; C. Reynolds; D. W. Yesair; S. W. Burgess; R. T. McKee; W. A. Shaw
Cancer Research | 2004
Hongtao Wang; Guoying Kong; C. Patrick Reynolds; Barry James Maurer
Archive | 2010
Barry James Maurer; Charles Patrick Reynolds
Archive | 2010
Barry James Maurer; Charles Patrick Reynolds